Valeo Pharma (TSE:VPH) has released an update.
Valeo Pharma has reported a record increase in Q2-2024 revenues, reaching $14.1 million, a 4% rise from the previous year, despite a higher adjusted EBITDA loss and a decrease in adjusted gross profit. The pharmaceutical company saw a significant upsurge in prescriptions of its asthma medications, Enerzair and Atectura, which more than doubled over the year. Valeo is undergoing a restructuring to enhance savings and bolster sales growth, setting the stage for a more profitable second half of the year.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.
